問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Study Site

Study Site



Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

Link to Hospital

  • 2,634

    Total Beds

  • 1,095

    Total Doctors

  • jmventcc@cgmh.org.tw
  • CHANG-CHIEN, CHIA-MIN
  • 07-7317123#6416
  • 833Kaohsiung CityKaohsiung NiaosongNo. 123, Dapi Rd., Niaosong Dist., Kaohsiung City 833 , Taiwan (R.O.C.)

Recruiting Trial

555Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1394Cases

2024-01-01 - 2027-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2017-05-01 - 2020-07-31

Phase III

Active
A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)

  • Condition/Disease

    Non Small Cell Lung Cancer NSCLC

  • Test Drug

    Durvalumab / Tremelimumab

Participate Sites
11Sites

Recruiting2Sites

Terminated8Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

楊政達
Linkou Chang Gung Medical Foundation

2024-01-01 - 2032-12-31

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting1Sites

2024-02-01 - 2026-07-27

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting1Sites

Terminated4Sites

2025-09-01 - 2027-05-31

Phase I/II

Active
A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients with Advanced Gastric and Gastroesophageal Cancer

  • Condition/Disease

    Gastric Cancer Adenocarcinoma Metastatic Gastroesophageal Adenocarcinoma

  • Test Drug

    BDC-4182

Participate Sites
6Sites

Recruiting6Sites

2024-03-01 - 2028-10-10

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting4Sites

Recruiting2Sites

2024-03-01 - 2027-11-10

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2024-03-15 - 2031-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Not yet recruiting1Sites

Recruiting9Sites

2025-12-01 - 2032-01-31

Phase II

Active
SEZanne: A Phase 2 Randomized, Open label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination with Atezolizumab versus Standard of Care as First-Line Treatment in Subjects with Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

  • Condition/Disease

    Small Cell Lung Cancer

  • Test Drug

    ABBV-706

Participate Sites
5Sites

Not yet recruiting1Sites

2024-04-01 - 2027-09-10

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

1 14 15 16 17 18 140
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB